Solos Endoscopy, Inc. Acquires Assets of CYduct, LLC

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

WESTPORT, CT / ACCESSWIRE / November 20, 2020 / Solos Endoscopy, Inc. (OTC PINK:SNDY) is pleased to announce that Solos' CEO and majority shareholder, Dominick Gatto, has contributed to Solos the extensive research and intellectual property of CYduct LLC, which he also controls. These assets are pertinent to Solos' future business interests.

CYduct, LLC, formed in 2018, is a development stage company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. With these CYduct assets Solos intends to focus on new strategic developments aimed at improving breast health and wellness, which could result in a new testing method that prioritizes clinical integrity and patient privacy and convenience. Incorporating this methodology in a medical device would further solidify our position within the breast healthcare market and complement our current MammoView product line," stated Dominick Gatto, Solos' Chief Executive Officer.

"The technology that CYduct has pursued would enable a physician, for the first time, in a clinical setting to easily record and analyze breast disease biomarkers. Such an analysis of the individualized mammary duct microenvironment chemistry, we believe would add significantly to current breast health risk assessment methods. It would provide physicians with the means to deliver personalized breast health care at its earliest possibility, potentially enhancing the lives of millions of women", said Mr. Gatto

About Solos Endoscopy, Inc.: Solos Endoscopy Inc. has long provided quality healthcare instruments to Hospitals across the United States. For more than 30 Years, from medical schools to hospitals, surgeons have relied on Solos Endoscopy to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products is available on the Company's website at:

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise, as well as the company's inability to raise additional capital, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Solos Endoscopy, Inc.
Investor Relations
(617) 360-9700

SOURCE: Solos Endoscopy, Inc.

View source version on

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).